4SC AG Actions en circulation
Quel est le Actions en circulation de 4SC AG?
Le Actions en circulation de 4SC AG est 50.570M
Quelle est la définition de Actions en circulation?
Les actions en circulation sont toutes les actions d'une société ou d'un actif financier qui ont été autorisées, émises et achetées par les investisseurs et qui sont détenues par eux.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Actions en circulation des entreprises dans Health Care secteur sur XETRA par rapport à 4SC AG
Que fait 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Entreprises avec actions en circulation similaire à 4SC AG
- Renewable Inc a Actions en circulation de 50.507M
- Gespeg Resources a Actions en circulation de 50.509M
- Cosmo Metals a Actions en circulation de 50.510M
- Cooper Tire & Rubber Co a Actions en circulation de 50.524M
- KFG Resources a Actions en circulation de 50.540M
- Cohen & Steers a Actions en circulation de 50.551M
- 4SC AG a Actions en circulation de 50.570M
- Tata Investment a Actions en circulation de 50.595M
- Tata Investment a Actions en circulation de 50.595M
- abrdn Healthcare Investors a Actions en circulation de 50.625M
- HeadHunter PLC a Actions en circulation de 50.636M
- Onxeo SA a Actions en circulation de 50.647M
- Forestar Inc a Actions en circulation de 50.654M